Uwe Klemm

Uwe Klemm

Auto-generated profile, based on publicly available information

Uwe Klemm

Chair of Biological Imaging Central Institute for Translational Cancer Research (TranslaTUM) School of Medicine and Health & School of Computation Information and Technology Technical University of Munich Munich Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
KMKanuj Mishra
Kanuj Mishra
MSMariia Stankevych
Mariia Stankevych
JFJuan Pablo Fuenzalida-Werner
Juan Pablo Fuenzalida-Werner
SGSimon Grassmann
Simon Grassmann
VGVipul Gujrati
Vipul Gujrati
ASAndre C. Stiel
Andre C. Stiel
Temporally unmixed optoacoustic enables routine in vivo imaging of transgene-labeled cells deep in the mouse body.

1 December 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ELEvangelos Liapis
Evangelos Liapis
UKUwe Klemm
Uwe Klemm
AKAngelos Karlas
Angelos Karlas
JRJosefine Reber
Josefine Reber
VNVasilis Ntziachristos
Vasilis Ntziachristos
Understanding temporal and spatial hemodynamic heterogeneity as a function of tumor growth or therapy affects the development of novel therapeutic strategies. In this study, we employed eigenspectra multispectral optoacoustic tomography (eMSOT) as a next-generation optoacoustic method to impart high accuracy in resolving tumor hemodynamics during bevacizumab therapy in two types of breast cancer xenografts (KPL-4 and MDA-MB-468). Patterns of tumor total hemoglobin concentration (THb) and oxygen saturation (sO2) were imaged in control and bevacizumab-treated tumors over the course of 58 days (KPL-4) and 16 days (MDA-MB-468), and the evolution of functional vasculature “normalization” was resolved macroscopically. An initial sharp drop in tumor sO2 and THb content shortly after the initiation of bevacizumab treatment was followed by a recovery in oxygenation levels. Rim–core subregion analysis revealed steep spatial oxygenation gradients in growing tumors that were reduced after bevacizumab treatment. Critically, eMSOT imaging findings were validated directly by histopathologic assessment of hypoxia (pimonidazole) and vascularity (CD31). These data demonstrate how eMSOT brings new abilities for accurate observation of entire tumor responses to challenges at spatial and temporal dimensions not available by other techniques today. Significance: Accurate assessment of hypoxia and vascularization over space and time is critical for understanding tumor development and the role of spatial heterogeneity in tumor aggressiveness, metastasis, and response to treatment.

8 May 2024 in IEEE Transactions on Medical Imaging
Verified
Journal Article
Open access
ATAnna Tenditnaya
Anna Tenditnaya
RGRuben Yannick Gabriels
Ruben Yannick Gabriels
WHWouter Hooghiemstra
Wouter Hooghiemstra
UKUwe Klemm
Uwe Klemm
WNWouter B. Nagengast
Wouter B. Nagengast
DGDimitris Gorpas
Dimitris Gorpas
Fluorescence molecular endoscopy (FME) is emerging as a “red-flag” technique with potential to deliver earlier, faster, and more personalized detection of disease in the gastrointestinal tract, including cancer, and to gain insights into novel drug distribution, dose finding, and response prediction. However, to date, the performance of FME systems is assessed mainly by endoscopists during a procedure, leading to arbitrary, potentially biased, and heavily subjective assessment. This approach significantly affects the repeatability of the procedures and the interpretation or comparison of the acquired data, representing a major bottleneck towards the clinical translation of the technology. Herein, we propose a robust methodology for FME performance assessment and quality control that is based on a novel multi-parametric rigid standard. This standard enables the characterization of an FME system’s sensitivity through a single acquisition, performance comparison of multiple systems, and, for the first time, quality control of a system as a function of time and number of usages. We show the photostability of the standard experimentally and demonstrate how it can be used to characterize the performance of an FME system. Moreover, we showcase how the standard can be employed for quality control of a system. In this study, we find that the use of composite fluorescence standards before endoscopic procedures can ensure that an FME system meets the performance criteria and that components prone to performance degradation are replaced in time, avoiding disruption of clinical endoscopy logistics. This will help overcome a major barrier for the translation of FME into the clinics.

4 February 2025 in Acta Biomaterialia
Verified
Journal Article
Open access
YHYishu Huang
Yishu Huang
MSMariia Stankevych
Mariia Stankevych
VGVipul Gujrati
Vipul Gujrati
UKUwe Klemm
Uwe Klemm
AMAzeem Mohammed
Azeem Mohammed
ASAndre C. Stiel
Andre C. Stiel
Optoacoustic imaging (OAI) is a unique in vivo imaging technique combining deep tissue penetration with high resolution and molecular sensitivity. OAI relying on strong intrinsic contrast, such as blood hemoglobin, already shows its value in medical diagnostics. However, OAI sensitivity to current extrinsic contrast agents is insufficient and limits its role in detecting disease-related biomarkers. The recently introduced concept of photoswitching and temporal unmixing techniques for OAI allows detecting extrinsic contrast with high sensitivity, allowing the visualization of small populations of cells labeled with photoswitching proteins deep within the tissue. However, transgene modification might not be permitted in some cases, such as for diagnostic use. Therefore, it is desirable to leverage the concept of photoswitching OAI towards injectable formulations. Since photoswitchable synthetic dyes are mainly excited by blue wavelengths unsuited for imaging in tissue, we propose exploiting the addition of XTENs to photoswitching proteins towards yielding injectable agents. The addition of XTEN to a protein enhances its plasma half-life and bioavailability, thus allowing its use, for example, in targeted labeling approaches. In this pilot study, we show that intravenously injected near-infrared absorbing photoswitchable proteins, ReBphP-PCM, coupled to XTEN, allow highly sensitive optoacoustic visualization of a tumor xenograft in vivo. The sensitivity to XTENs-ReBphP-PCM determined by ex vivo analysis of labeled cells is one to two orders of magnitude beyond conventional synthetic dyes used currently in OAI. The enhanced sensitivity afforded by photoswitching OAI, in combination with the increased bioavailability and biocompatibility of XTENs-ReBphP-PCM, makes this fusion protein a promising tool for facilitating sensitive detection of biomarkers in OAI with a potential for future use in diagnostics. STATEMENT OF SIGNIFICANCE: Optoacoustic imaging (OAI) is a unique in vivo imaging technique that combines deep tissue penetration with high resolution. OAI, which relies on intrinsic contrast, such as blood hemoglobin, could already be valuable in medical diagnostics. However, the use of extrinsic contrast agents to augment disease-related biomarkers in research and diagnostics suffers from very limited sensitivity of the generated contrast agent. We present an intravenously injected photoswitchable protein, ReBphP-PCM, coupled to XTEN, allowing highly sensitive OAI. The sensitivity is one to two orders of magnitude greater than that of conventional synthetic dyes used currently in OA imaging. The high sensitivity afforded by photoswitching together with the enhanced bioavailability and biocompatibility of the XTENs-ReBphP-PCM make this a standard agent for high-quality detection of OAI with potential for clinical use.


28 October 2026 in Advanced Functional Materials
Verified
Journal Article
Open access
DSDivyesh Shelar
Divyesh Shelar
SSSnehal Salunkhe
Snehal Salunkhe
TFTony Fröhlich
Tony Fröhlich
UKUwe Klemm
Uwe Klemm
PAPia Anzenhofer
Pia Anzenhofer
VNVasilis Ntziachristos
Vasilis Ntziachristos
Near‐infrared (NIR) cyanine dyes demonstrate considerable promise in medical applications, notably in cancer diagnosis, due to their favourable fluorescence properties and biocompatibility. However, these dyes generally have low photostability and tend to aggregate in aqueous solution, which can constrain their usefulness for prolonged in vivo imaging and phototherapy applications. Here, we report the synthesis of a selenium‐integrated NIR cyanine dye, Se‐Cyn, designed to modulate its electronic and photophysical properties. Se‐Cyn demonstrates high photostability, molar absorptivity, photothermal conversion efficiency (PCE), and sustained optoacoustic (OptA) contrast under prolonged irradiation. Se‐Cyn nanoparticles (NPs) outperform the indocyanine green (ICG) NPs, exhibiting PCE of 59% and a 1.36‐fold higher OptA generation efficiency. Additionally, nano‐formulated Se‐Cyn NPs show excellent aqueous stability and improved bioavailability, supporting its suitability for biological applications. Furthermore, Se‐Cyn NPs accumulate in tumors following systemic administration, enabling effective OptA tumor imaging. Together with their strong photodynamic and photothermal properties, these NPs show considerable potential for cancer theranostics.